ライフサイエンスコーパス: loperamide

1 ant diarrhea did not occur with prophylactic loperamide.

2 istered twice daily by mouth with concurrent loperamide.

3 grade symptoms can be managed with continued loperamide.

4 ted at 24 mg/m(2), despite aggressive use of loperamide.

5 cyclosporin A, ondansetron, domperidone, and loperamide.

6 try of the PET radiotracer (11)C-N-desmethyl-loperamide ((11)C-dLop).

7 s metabolism to [N-methyl-(11)C] N-desmethyl-loperamide ([(11)C]dLop; [(11)C]3) precludes quantificat

8 it is rapidly metabolized to 11C-N-desmethyl-loperamide (11C-dLop), which is also a substrate for P-g

9 trials), psychotropic agents (7 trials), and loperamide (4 trials).

10 at Cereport was able to increase delivery of loperamide across the BBB, allowing it to gain access to

11 o diminish by 120 min following Cereport and loperamide administration.

12 Loperamide alone did not produce analgesia.

13 Aggressive administration of loperamide also reduced the incidence of grade 4 diarrhe

14 Loperamide, an opiate receptor agonist, does not cross t

15 ict adherence to an antidiarrheal regimen of loperamide and diphenyldramine.

16 brain barrier, P-gp blocks the entry of both loperamide and its metabolite, N-desmethyl-loperamide (N

17 Both 11C-loperamide and its putative radiometabolite 11C-dLop are

18 The brain concentrations of 11C-loperamide and the putative 11C-dLop were about 16-fold

19 ry, repeated--assessment, appropriate use of loperamide, and knowledge of fluid resuscitation require

20 Monkeys were injected with 11C-loperamide, and PET brain images were acquired for 120 m

21 For three P-gp substrates (amprenavir, loperamide, and quinidine), we have successfully fitted

22 We evaluated 11C-loperamide as a PET radiotracer to measure P-gp function

23 Loperamide at 10-30 microM has no effect on intracellula

24 se of irinotecan 125 mg/m2 and by initiating loperamide at the earliest signs of diarrhea.

25 It appears that loperamide augments influx of calcium through activated

26 Only in astrocytoma cells did loperamide cause an elevation in intracellular calcium i

27 Loperamide caused augmentation of intracellular calcium

28 Antidiarrheal agents (including loperamide, diphenoxylate, and difenoxin) and the tricyc

29 The radiotracer [(11)C]N-desmethyl-loperamide (dLop) images the in vivo function of P-glyco

30 d selective P-gp substrate (11)C-N-desmethyl-loperamide (dLop) while avoiding side effects associated

31 and trifluoperazine) that in the absence of loperamide effectively blocked SOC channels.

32 s, (3)H-verapamil (threefold increase), (3)H-loperamide (fivefold increase), and (3)H-paclitaxel (fiv

33 ually a fluoroquinolone or azithromycin, and loperamide for rapid resolution of symptoms.

34 [(11)C]Loperamide has been proposed for imaging P-glycoprotein

35 Loperamide has no effect when levels of intracellular ca

36 rged, among them that methadone, emetine and loperamide (Imodium) may antagonize muscarinic M3, alpha

37 ntation of intracellular calcium elicited by loperamide in cultured cells was dependent on extracellu

38 11C-dLop may be superior to 11C-loperamide in measuring P-gp function at the blood-brain

39 ent choices for diarrhea management included loperamide in the majority of patients.

40 and partly with the CES2-specific inhibitor loperamide, indicating that carboxylesterase Ces2a, whic

41 netic studies with the Mdr1a P-gp substrates loperamide, indinavir, and talinolol indicated that Mdr1

42 11C-Loperamide is an avid substrate for P-glycoprotein (P-gp

43 Loperamide is effective for diarrhea.

44 e shown that (11)C-dLop, compared with (11)C-loperamide, is an especially promising radiotracer becau

45 (1650 mg; 107 persons), in combination with loperamide (labeled dosing).

46 Treatment with Loperamide, low-fiber diets, and bile salt- binding ther

47 10 muL of whole blood containing citalopram, loperamide, methadone, and sertraline as model substance

48 1.2, 5.5, 2.0, and 5.3 ng/mL for citalopram, loperamide, methadone, and sertraline, respectively.

49 h loperamide and its metabolite, N-desmethyl-loperamide (N-dLop), and thereby prevents central opiate

50 , the apparent positive modulatory effect of loperamide on SOC channels occurs when these channels ha

51 0 g in those with constipation, those taking loperamide or other opioids for diarrhea, and those taki

52 ice with NG-nitro-L-arginine methyl ester or loperamide prevented both the increased motility and the

53 inistration of a combination of Cereport and loperamide produced a significant analgesic effect (2-fo

54 rring in 21% of patients taking prespecified loperamide prophylaxis and 28% of those without prophyla

55 ndividual patient tolerance and an intensive loperamide regimen for the management of diarrhea.

56 Loperamide remains the standard therapy for uncomplicate

57 Loperamide seems to reduce diarrhea but does not relieve

58 an antidiarrheal regimen of diphenhydramine/loperamide significantly reduced the incidence of diarrh

59 the uptake of the known P-gp substrate (11)C-loperamide, suggesting that the effects of disulfiram in

60 y of the peripherally acting opiate agonist, loperamide, to the brain, as evidenced by induction of a

61 ithromycin, levofloxacin, and rifaximin with loperamide were comparable for treatment of acute watery

62 analgesic effects of combining Cereport and loperamide were completely blocked when animals were pre